|
|
#1 |
|
Senior Member
|
SDN Members don't see this ad. (About Ads)
|
|
|
|
|
|
#2 | |
|
No Meat, No Treat
|
Quote:
1. I like the patient contact and continuity. 2. I still look at a lot of smears, marrows and biopsies, but its for my own edification and education...the buck doesn't stop with me on that front. 3. As an oncologist, I won't have any trouble finding a job when I finish training. As a path resident, I'd be looking at 1-3 more years of fellowship with minimal hope of a job. |
|
|
|
|
|
|
#3 | |
|
Senior Member
|
Quote:
I was thinking that oncology might be frustrating because oncologists don't really diagnose their patients and chemotherapy seems to be very empirical (in that there are only a few targeted therapies like Gleevec). Well, the job market for pathology is not that good, but statistically nearly all pathologists find a job... just not necessarily in the location that they wanted. I guess it is still pretty edifying to look at a slide even though you are not responsible for signing it out. I guess that most clinicians routinely look at their imaging studies, but maybe only heme/onc regularly looks at slides/smears. Isn't the patient contact in oncology pretty dark? I would think that it would be pretty emotionally draining. Maybe I'm just not that much of a people person, but it seems to me that oncology is very heavy on the emotional interaction with dying patients. Don't you ever wish to just be on the purely scientific unemotional side of the equation? Maybe I'm just not appreciating the draw of this type of patient interaction. Last edited by Enkidu; 05-01-2011 at 01:12 PM. |
|
|
|
|
|
|
#4 | ||||||
|
No Meat, No Treat
|
Quote:
Quote:
About half of inpatient consults go like this "I have a guy with a (insert organ/anatomical site) mass on CT, can you come figure out what he has and how to treat him?" The other half are from surgeons asking you to figure out why a patient with an INR of 5 and platelets of 12 is having post-op bleeding. At that point it's kind of semantic as to who "diagnoses" the patient. You're going to write a note stating what the most likely dx is (and you're probably already warming up your favorite treatment cocktail). The radiologist who read the CT scan probably already said "suspicious for X-inoma." Then a surgeon, GI, pulm or radiologist will get a hunk of that tissues. Then the pathologist will look at it under the scope, maybe run an IHC or two (or 12 if they have good insurance) and pronounce it to be "definitely X-inoma." Of the 3-5 people who laid their hands on that case, who "made the diagnosis?" Who cares? As for targeted therapies...rituximab, sorafenib, sunitinib, cetuximab, panitumumab, pazopanib, ipilimumab, erlotinib, trastuzumab, bevacizumab...let me know if you want me to stop. Quote:
Quote:
Quote:
It can be tough, sure, but it can also be quite edifying both to help cure people (which happens although not as often as we'd like) as well as to help people have a good death. But yes, you need to have some people skills and a fair amount empathy in order to do it. I'm probably the wrong person to ask about this though because my clinical and research focus are on advanced and metastatic GI malignancies so I probably have a different perspective and tolerance for this part of the job. Quote:
I went through this same thought process when I was finishing up grad school and headed back to med school. Lots of people that I respected (including my PhD advisor and a close collaborator) told me I should do path since it would be the fastest route back to the lab. But I like the patient interaction too much to give it up. |
||||||
|
|
|
|
|
#5 |
|
Senior Member
|
Interesting points. I guess that my perspective on oncology is based on my experience in pathology. Thanks for being polite about my talking out of my ****, I admit that I never considered going into oncology. My interest is secondary to my interest in path.
The majority of cancers don't have targeted therapies, though. Isn't that right? That's the impression I got from medical school, at least. Based on your characterization it seems like you consider pathology to be tantamount to a laboratory test confirming your clinical impressions. How accurate are your clinical impressions when it comes to classifying a tumor? |
|
|
|
|
|
#6 | |
|
Member
|
Quote:
Pathology should be compared with radiology/radiation oncology etc (fields with no patient contact).....Onc is a field full of pt contact which is fun (People in other field think Onc pt encounter is depressing, but thats not true). pt exposure with Onc pt is the most diverse/fun experience to me. You see a young 19 yr old with Hodgkin going for ABVD to 90 yr old grandpa with prostate cancer on casodez |
|
|
|
|
|
|
#7 | |
|
1K Member
|
Quote:
|
|
|
|
|
|
|
#8 | |
|
No Meat, No Treat
|
Quote:
Now...they do often have minimal follow-up once they're done zapping...that usually gets left to us. But getting them re-involved is easy. |
|
|
|
|
|
|
#9 | |
|
Member
|
Quote:
True to some extent, But I see their role as helping guest in life of cancer pt...Agree with 1 1/2 hr consult for radiation planning....Pathologist may say they get pt encounter when they come for frozen section in OR and they spend time with pt's tissue (if they consider that encounter)....But comparing radiologist pt encounter to med Onc doc will not be fair...Oncolgist role is different...In radiation dept, pts time is spent with machine and tech.....MD see them at start and end of treatment |
|
|
|
|
|
|
#10 |
|
Senior Member
|
Well, the amount of patient contact is pretty irrelevant to this question. Pathology delivers the definitive diagnosis of cancer and oncology provides the medical treatment. That is the link between them. My question is whether many oncologists wish they were signing out the tissue rather than providing the chemotherapy and emotional support.
I don't know of many pathologists that desire patient encounters, because they get the satisfaction of having the final say in the patients diagnosis. Maybe oncologists are the same in that they don't mind relying on a diagnosis from pathology because they get to treat the patient and have those patient encounters. As for there being a semantic ambiguity in the question of who makes the diagnosis, to be honest I don't see it that strongly. Regardless of the clinical impression, the final diagnosis is made based on the tissue. If the oncologist is proved right by pathology, then I suppose they can feel pretty good about their clinical acumen, but ultimately the patient is treated for what the pathologist diagnosed him with. At least that's what I think. Would some oncologists ignore a tissue diagnosis and instead treat the patient based on their clinical impression? |
|
|
|
|
|
#11 | |
|
No Meat, No Treat
|
Quote:
If you had just said at the beginning that all you wanted to do was start an irrelevant fight over this non-issue, we could have ended this much more quickly and you could have gotten back to masturbating furiously to Robbins while the rest of us got on with our lives. |
|
|
|
|
|
|
#12 | |
|
Senior Member
|
Quote:
My impression from this thread was that oncologists don't consider that pathologists necessarily diagnose cancer any more than they do, and that pathology can't even be compared to oncology because pathologists don't have patient contact. I guess that this surprised me. After you took issue with my characterization of pathology as "diagnosing" cancer, I switched my usage to "definitive" or "final" diagnosis of cancer. I guess I'm not really sure how to specify the role of pathology any more clearly. |
|
|
|
|
|
|
#13 | |
|
Senior Member
Join Date: Feb 2007
Posts: 173
|
Quote:
To answer your question, no, most oncologists do not with they were doing pathology. They are two very different fields and probably attract different personalities. |
|
|
|
|
|
|
#14 |
|
Senior Member
|
To be fair, these 'targeted therapies', though better than cytotoxics, aren't really cancer specific like say antibiotics are bacteria-specific. Shutting down VEGF is like turning off the plumbing to fix a leak (except the leak is an evolving expanding mass full of plumbing encroaching on your rooms!). Imatinib was the first truly specific, and thus exciting biologic, at least in my eyes.
|
|
|
|
|
|
#15 | |
|
No Meat, No Treat
|
Quote:
That's why I actually tend to use the phrase "biologic therapies" because they're not targeted. |
|
|
|
|
|
|
#16 | |
|
Senior Member
|
Quote:
|
|
|
|
|
|
|
#17 | |
|
Senior Member
|
Quote:
I'm glad I found this thread. I'm doing the PSF program right now, and am interested in heading towards IM then Heme/Onc. I enjoyed the Heme Path rotation, but I'm starting to miss seeing people...Maybe third year will make me miss NOT seeing people though. |
|
|
|
|
|
|
#18 | |
|
16th centry dutch painter
Join Date: Feb 2003
Posts: 1,531
|
Quote:
Easier on my monthly budget too. I think TKI side effects can be nastier than chemo, depending on the drug/dose. Their toxicity profile is different, not necessarily better. I will agree that monoclonal abs or antibody-drug conjugates are well tolerated.
Last edited by carrigallen; 10-25-2011 at 01:18 PM. |
|
|
|
|
![]() |
| Bookmarks |
«
Previous Thread
|
Next Thread
»
| Thread Tools | |
| Display Modes | |
|
|
All times are GMT -7. The time now is 06:05 AM.





Easier on my monthly budget too. I think TKI side effects can be nastier than chemo, depending on the drug/dose. Their toxicity profile is different, not necessarily better. I will agree that monoclonal abs or antibody-drug conjugates are well tolerated.





Linear Mode

